UTv Videos

“I think one of the biggest challenges women have in general in terms of diagnosis of bladder cancer is that it tends to be delayed,” says Ava Saidian, MD.

"If you are going to be an inclusive leader...it's important that you think about those gaps in education and hopefully try to fill those," says Denise Asafu-Adjei, MD, MPH.

"I think that using this database does allow for some generalizability, and we're pretty confident in that," says Evan Panken, MD.

Raevti Bole, MD, recently presented a talk at the SMSNA Fall Scientific Meeting on nonsurgical BPH management.

"The communication piece is everything," says Amy Pearlman, MD.

"The biggest complaint we saw, as far as negative outcomes, was loss of length," says Landon Trost, MD.

Bridget Koontz, MD, highlights the design and enrollment criteria of the ongoing phase 2 NRG-GU011 trial.

“The preliminary findings were quite favorable in that we saw, especially in the low-grade population, complete elimination of tumor cells on the biopsies, on the transurethral resection of bladder tumors,” says Gary D. Steinberg, MD.

"With Aquablation, because of the real-time ultrasound image and the 3D animation that's created, you can see the actual dimensions and shape of the tunnel that's created before you even start the procedure," says Ravi Munver, MD.

“After doing a literature review about cystectomy patients and how devastating it is for female sexual function after having a cystectomy, [my main takeaway from this study is that] it seems that women tolerate the intravesical treatments well,” says Talia A. Helman, MD.

"The most significant rate of burnout has increased in female urologists," says Marah C. Hehemann, MD.

"What we found [with] 78 patients [was] that patient satisfaction was the same whether you place it in the prevesical space or the ectopic space," says Mohit Khera, MD, MBA, MPH.

"This study is significant because it really emphasizes the importance of early detection of both BPH and ED, because knowing that information can really preserve men's quality of life," says Olivia Paulsen.

“Nowadays with PET, it's not perfect, but even with a PSA less than 1 ng/mL, we can detect the site of recurrence about 2/3 of the time,” says Bridget Koontz, MD.

"We found an increased association with AKI or acute kidney injury in the group receiving testosterone replacement therapy," said Evan Panken, MD.

Bajic summarizes his 2024 Sexual Medicine Society of North America Fall Scientific Meeting talk “Penile Prosthesis Biofilms: Friend or Foe?”

"What we found is that costs have really dramatically decreased year by year for all 3 medications," says Ellen Cahill, MD.

"You've got a double pronged attack to kill cancer cells, which is in line with our concepts of immunologic care and immunologic treatment in a variety of cancers, especially cancers such as bladder cancer," says Gary D. Steinberg, MD.

"I think patient preference is going to be the most important thing here," says Raevti Bole, MD.

"We're also dealing with some cultural biases, and we have to be mindful [of] how do people like to discuss sexual medicine, and how does that impact our patient interactions?" says Denise Asafu-Adjei, MD, MPH.

"Having a digital footprint is one of the most important things we can do as health care providers," says Amy Pearlman, MD.

"I think it's great, actually, that finally, we have more data on nutrition that we can recommend to our patients," says Stacy Loeb, MD, MSc, PhD (hon).

"Looking at the survey results, we found that about 40% of men under the age of 40 are interested, at least, in supplementing their testosterone," says Justin Dubin, MD.

"We see [urinary incontinence] in up to 62% of US women, and we know that in women with incontinence, about 25% report that it negatively impacts their sexual health," says Ramzy T. Burns, MD.

"The TRAVERSE trial is the largest randomized placebo-controlled trial ever published in men receiving testosterone vs placebo," says Mohit Khera, MD, MBA, MPH.

"As with any drug, I think there's a big learning curve that comes anytime something's approved," says Landon Trost, MD.

“Particularly [in] bladder cancer, there's 2 new drugs on the market that are exceptionally expensive, but they do provide benefit to patients,” says Geoffrey N. Sklar, MD, FACS.